The Nippon Chemiphar Group is pursuing the designated three main areas of business: generics, diagnostics, and new drugs including alkalization therapy and by expanding these lines of business areas overseas, we are attaining sustainable development and maximizing our corporate value. As “pharmaceutical” being the keyword, by simultaneously operating these three business areas, each with its own timeline, we believe we can build a business model with incomparable value for all our stakeholders.

Reflecting on the financial results for FY2024, although our earnings performance was affected by NHI drug price revisions, sales grew as a result of the boost we received from our sales of generics focused on expansion and recently launched products, in addition to the further solid market penetration by our revolutionary DropScreen allergy screening kit. Thus, we achieved a return to profitability at both the operating profit and ordinary profit levels, as well as for profit attributable to owners of the parent. Further, our development pipeline in the new drug business has progressed and expanded significantly over the past few years.

As for FY2025, as our major priority, we will continue ensuring stable supply of high-quality products. Our earnings base will be strengthened through further sales of our generics focused on expansion and recently launched products as well as additional promotion of DropScreen in Japan.

We look forward to your continued support.

Kazushiro Yamaguchi
President&CEO